MD - MEDNAX, Inc.
NYSE
->
Healthcare
->
Medical Care Facilities
Sunrise,
United States
Type: Equity
MD price evolution
MD
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $73.26 | $21.18 | $5.85 | $6.12 |
| Short term investments | $104.48 | $103.54 | $98.49 | $96.71 |
| Net receivables | $272.31 | $277.35 | $270.85 | $278.74 |
| Inventory | ||||
| Total current assets | $483.45 | $420.52 | $397.77 | $408.59 |
| Long term investments | ||||
| Property, plant & equipment | $145.93 | $147.59 | $140.42 | $139.72 |
| Goodwill & intangible assets | $1405.41 | $1547.58 | $1548.89 | $1549.58 |
| Total noncurrent assets | $1736.36 | $1905.82 | $1907.74 | $1911.46 |
| Total investments | $104.48 | $103.54 | $98.49 | $96.71 |
| Total assets | $2219.81 | $2326.34 | $2305.51 | $2320.05 |
| Current liabilities | ||||
| Accounts payable | $350.8 | $302.58 | $277.68 | $226.68 |
| Deferred revenue | ||||
| Short long term debt | $35.99 | $36.74 | $36.49 | $35.97 |
| Total current liabilities | $388.95 | $350.44 | $320.32 | $284.22 |
| Long term debt | $665.66 | $670.18 | $709.34 | $786.79 |
| Total noncurrent liabilities | $981.8 | $1007.91 | $1042.82 | $1126.06 |
| Total debt | $701.65 | $706.92 | $745.83 | $822.76 |
| Total liabilities | $1370.75 | $1358.35 | $1363.13 | $1410.28 |
| Shareholders' equity | ||||
| Retained earnings | -$149.47 | -$25.18 | -$46.58 | -$74.86 |
| Other shareholder equity | -$2.21 | -$3.52 | -$3.52 | -$3.13 |
| Total shareholder equity | $849.06 | $967.99 | $942.38 | $909.77 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $73.26 | $9.82 | $387.39 | $1123.84 |
| Short term investments | $104.48 | $93.24 | $99.72 | $104.87 |
| Net receivables | $272.31 | $296.79 | $301.77 | $241.93 |
| Inventory | ||||
| Total current assets | $483.45 | $427.99 | $840.56 | $1549.35 |
| Long term investments | ||||
| Property, plant & equipment | $145.93 | $140.21 | $135.62 | $132.16 |
| Goodwill & intangible assets | $1405.41 | $1550.58 | $1526.99 | $1504.61 |
| Total noncurrent assets | $1736.36 | $1919.9 | $1881.98 | $1798.6 |
| Total investments | $104.48 | $93.24 | $99.72 | $104.87 |
| Total assets | $2219.81 | $2347.89 | $2722.55 | $3347.95 |
| Current liabilities | ||||
| Accounts payable | $350.8 | $31.86 | $394.12 | $423.16 |
| Deferred revenue | ||||
| Short long term debt | $35.99 | $36.49 | $22.17 | $21.15 |
| Total current liabilities | $388.95 | $426.98 | $427.37 | $444.33 |
| Long term debt | $665.66 | $636.38 | $1043.65 | $1783.56 |
| Total noncurrent liabilities | $981.8 | $1029.27 | $1398.49 | $2155.9 |
| Total debt | $701.65 | $717.08 | $1065.83 | $1804.71 |
| Total liabilities | $1370.75 | $1456.26 | $1825.85 | $2600.23 |
| Shareholders' equity | ||||
| Retained earnings | -$149.47 | -$89.06 | -$155.39 | -$286.35 |
| Other shareholder equity | -$2.21 | -$3.73 | $1.32 | $3.53 |
| Total shareholder equity | $849.06 | $891.63 | $896.49 | $747.49 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $496.44 | $506.61 | $500.58 | $491.01 |
| Cost of revenue | $395.28 | $399.72 | $385.12 | $392.95 |
| Gross Profit | $101.17 | $106.89 | $115.46 | $98.05 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $53.06 | $57.41 | $58.01 | $59.06 |
| Total operating expenses | $212.66 | $66.62 | $66.96 | $68.01 |
| Operating income | -$111.49 | $40.27 | $48.5 | $30.04 |
| Income from continuing operations | ||||
| EBIT | -$128.77 | $41.21 | $50.18 | $31.1 |
| Income tax expense | -$14.56 | $9.44 | $10.66 | $6.51 |
| Interest expense | $10.08 | $10.37 | $11.23 | $10.39 |
| Net income | ||||
| Net income | -$124.29 | $21.39 | $28.28 | $14.21 |
| Income (for common shares) | -$124.29 | $21.39 | $28.28 | $14.21 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1994.64 | $1972.02 | $1911.19 | $1733.95 |
| Cost of revenue | $1573.08 | $1504.99 | $1397.95 | $1284.63 |
| Gross Profit | $421.56 | $467.03 | $513.24 | $449.32 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $227.54 | $231.4 | $263.36 | $248.95 |
| Total operating expenses | $414.24 | $294.35 | $310.32 | $351.19 |
| Operating income | $7.32 | $172.69 | $202.92 | $98.13 |
| Income from continuing operations | ||||
| EBIT | -$6.28 | $124.84 | $226.93 | -$669.28 |
| Income tax expense | $12.05 | $18.81 | $27.24 | $16.73 |
| Interest expense | $42.08 | $39.7 | $68.72 | $110.48 |
| Net income | ||||
| Net income | -$60.41 | $66.33 | $130.96 | -$796.49 |
| Income (for common shares) | -$60.41 | $66.33 | $130.96 | -$796.49 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$124.29 | $21.39 | $28.28 | $14.21 |
| Operating activities | ||||
| Depreciation | $9.06 | $9.21 | $8.95 | $8.95 |
| Business acquisitions & disposals | -$5 | -$1.67 | ||
| Stock-based compensation | $3.02 | $3.16 | $3.13 | $3.01 |
| Total cash flows from operations | $69.25 | $79.94 | $89.05 | -$100.92 |
| Investing activities | ||||
| Capital expenditures | -$9.04 | -$9.15 | -$8.13 | -$7 |
| Investments | $0.93 | -$4.97 | -$2.27 | -$2.68 |
| Total cash flows from investing | -$12.42 | -$14 | -$10.4 | -$11.35 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.04 | $1.05 | $1.58 | $0.32 |
| Net borrowings | -$3.64 | -$44.83 | -$76.83 | $106.17 |
| Total cash flows from financing | -$4.75 | -$50.6 | -$78.93 | $108.57 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $52.08 | $15.33 | -$0.28 | -$3.7 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$60.41 | $66.33 | $130.96 | -$796.49 |
| Operating activities | ||||
| Depreciation | $36.17 | $35.64 | $32.15 | $28.44 |
| Business acquisitions & disposals | -$6.67 | -$28.17 | -$29.93 | -$1.15 |
| Stock-based compensation | $12.32 | $16.13 | $18.97 | $39.04 |
| Total cash flows from operations | $137.32 | $166.94 | $76.74 | $204.62 |
| Investing activities | ||||
| Capital expenditures | -$33.33 | -$29.71 | -$7.52 | -$28.79 |
| Investments | -$8.99 | -$0.46 | -$18.56 | -$28.41 |
| Total cash flows from investing | -$48.18 | -$56.95 | -$53.07 | $815.51 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.99 | -$83.11 | $2.13 | -$1.48 |
| Net borrowings | -$19.12 | -$413.79 | -$762.66 | -$1.67 |
| Total cash flows from financing | -$25.71 | -$487.55 | -$760.12 | -$4.16 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $63.43 | -$377.57 | -$736.45 | $1015.97 |
News
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Zacks via Yahoo Finance
31 Mar 2023
|
|
Mednax (MD) Q2 Earnings Match Estimates
Zacks via Yahoo Finance
4 Aug 2022
|
|
Mednax (MD) Reports Next Week: Wall Street Expects Earnings Growth
Zacks via Yahoo Finance
16 Jul 2022
|
|
Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap...
Zacks via Yahoo Finance
11 Jul 2022
|
|
Will Mednax's (MD) New Name Pediatrix Medical be Beneficial?
Zacks via Yahoo Finance
23 Jun 2022
|
|
7 Cheap Stocks Under $20 That Could Double Soon
InvestorPlace via Yahoo Finance
7 Jun 2022
|
|
Does The Market Have A Low Tolerance For MEDNAX, Inc.'s (NYSE:MD) Mixed Fundamentals?
Simply Wall St. via Yahoo Finance
4 May 2022
|
|
74 Biggest Movers From Yesterday
Benzinga
29 Apr 2022
|
|
Mednax (MD) Q1 Earnings and Revenues Surpass Estimates
Zacks via Yahoo Finance
28 Apr 2022
|
|
48 Stocks Moving In Thursday's Mid-Day Session
Benzinga
28 Apr 2022
|
Fundamentals
| Market cap | $776.33M |
|---|---|
| Enterprise value | $1.40B |
| Shares outstanding | 84.02M |
| Revenue | $1.99B |
|---|---|
| EBITDA | $29.89M |
| EBIT | -$6.28M |
| Net Income | -$60.41M |
| Revenue Q/Q | -3.39% |
| Revenue Y/Y | 1.15% |
| P/E ratio | -12.85 |
|---|---|
| EV/Sales | 0.70 |
| EV/EBITDA | 47.00 |
| EV/EBIT | -223.54 |
| P/S ratio | 0.39 |
| P/B ratio | 0.91 |
| Book/Share | 10.13 |
| Cash/Share | 0.87 |
| EPS | -$0.72 |
|---|---|
| ROA | -2.63% |
| ROE | -6.59% |
| Debt/Equity | 1.61 |
|---|---|
| Net debt/EBITDA | 43.41 |
| Current ratio | 1.24 |
| Quick ratio | 1.24 |